1. Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multicentre, non-inferiority clinical trial undertaken in the primary healthcare setting (Project OB12)
- Author
-
Sanz-Cuesta Teresa, González-Escobar Paloma, Riesgo-Fuertes Rosario, Garrido-Elustondo Sofía, del Cura-González Isabel, Martín-Fernández Jesús, Escortell-Mayor Esperanza, Rodríguez-Salvanés Francisco, García-Solano Marta, González-González Rocío, Martín-de la Sierra-San Agustín María, Olmedo-Lucerón Carmen, Palmero María Luisa, Mateo-Ruiz Carmen, Medina-Bustillo Beatriz, Valdivia-Pérez Antonio, Blas-González Francisca, Mariño-Suárez José, Rodríguez-Barrientos Ricardo, Ariza-Cardiel Gloria, Cabello-Ballesteros Luisa, Polentinos-Castro Elena, Rico-Blázquez Milagros, Rodríguez-Monje Ma, Soto-Díaz Sonia, Martín-Iglesias Susana, Rodríguez-González Ramón, Bretón-Lesmes Irene, Vicente-Herrero María, Sánchez-Díaz Jesús, Gómez-Gascón Tomás, Drake-Canela Mercedes, and Barco Ángel
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background The oral administration of vitamin B12 offers a potentially simpler and cheaper alternative to parenteral administration, but its effectiveness has not been definitively demonstrated. The following protocol was designed to compare the effectiveness of orally and intramuscularly administered vitamin B12 in the treatment of patients ≥65 years of age with vitamin B12 deficiency. Methods/design The proposed study involves a controlled, randomised, multicentre, parallel, non-inferiority clinical trial lasting one year, involving 23 primary healthcare centres in the Madrid region (Spain), and patients ≥65 years of age. The minimum number of patients required for the study was calculated as 320 (160 in each arm). Bearing in mind an estimated 8-10% prevalence of vitamin B12 deficiency among the population of this age group, an initial sample of 3556 patients will need to be recruited. Eligible patients will be randomly assigned to one of the two treatment arms. In the intramuscular treatment arm, vitamin B12 will be administered as follows: 1 mg on alternate days in weeks 1 and 2, 1 mg/week in weeks 3–8,and 1 mg/month in weeks 9–52. In the oral arm, the vitamin will be administered as: 1 mg/day in weeks 1–8 and 1 mg/week in weeks 9–52. The main outcome variable to be monitored in both treatment arms is the normalisation of the serum vitamin B12 concentration at weeks 8, 26 and 52; the secondary outcome variables include the serum concentration of vitamin B12 (in pg/ml), adherence to treatment, quality of life (EuroQoL-5D questionnaire), patient 3satisfaction and patient preferences. All statistical tests will be performed with intention to treat and per protocol. Logistic regression with random effects will be used to adjust for prognostic factors. Confounding factors or factors that might alter the effect recorded will be taken into account in analyses. Discussion The results of this study should help establish, taking quality of life into account, whether the oral administration of vitamin B12 is an effective alternative to its intramuscular administration. If this administration route is effective, it should provide a cheaper means of treating vitamin B12 deficiency while inducing fewer adverse effects. Having such an alternative would also allow patient preferences to be taken into consideration at the time of prescribing treatment. Trial registration This trial has been registered with ClinicalTrials.gov, number NCT 01476007, and under EUDRACT number 2010-024129-20.
- Published
- 2012
- Full Text
- View/download PDF